# Nicholas J Maragakis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5894797/publications.pdf

Version: 2024-02-01

| 87 | 8,706 | 66343 | 54911 |
|---|---|---|---|
| papers | citations | 42 h-index | 84 g-index |

| 91 | 91 | 91 | 10927 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Human induced pluripotent stem cellâ€“derived astrocytes progenitors as discovery platforms. , 2022, , 45-89. | | 0 |
| 2 | Exploring Motor Neuron Diseases Using iPSC Platforms. Stem Cells, 2022, 40, 2-13. | 3.2 | 6 |
| 3 | Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells. Molecular Neurodegeneration, 2022, 17, 8. | 10.8 | 10 |
| 4 | Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience, 2022, 25, 226-237. | 14.8 | 66 |
| 5 | Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2107391119. | 7.1 | 29 |
| 6 | Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186. | 9.0 | 79 |
| 7 | Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neuroscience Letters, 2021, 755, 135911. | 2.1 | 20 |
| 8 | Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236. | 9.0 | 46 |
| 9 | Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons. Journal of Visualized Experiments, 2021, , . | 0.3 | 5 |
| 10 | Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831. | 10.2 | 9 |
| 11 | MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegenerative Disease Management, 2021, 11, 431-443. | 2.2 | 16 |
| 12 | Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nature Neuroscience, 2021, 24, 1673-1685. | 14.8 | 38 |
| 13 | Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. Experimental Neurology, 2020, 323, 113091. | 4.1 | 9 |
| 14 | Primary lateral sclerosis (PLS) functional rating scale: PLSâ€specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172. | 2.2 | 17 |
| 15 | Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle and Nerve, 2020, 62, 156-166. | 2.2 | 60 |
| 16 | Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2020, 79, 266-276. | 1.7 | 17 |
| 17 | Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186. | 2.2 | 42 |
| 18 | Role of Human-Induced Pluripotent Stem Cell-Derived Spinal Cord Astrocytes in the Functional Maturation of Motor Neurons in a Multielectrode Array System. Stem Cells Translational Medicine, 2019, 8, 1272-1285. | 3.3 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Analyzing progression of motor and speech impairment in ALS. , 2019, 2019, 6097-6102. | | 5 |
| 20 | Perfluorocarbon Labeling of Human Glial-Restricted Progenitors for 19F Magnetic Resonance Imaging. Stem Cells Translational Medicine, 2019, 8, 355-365. | 3.3 | 11 |
| 21 | Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6. | 8.1 | 517 |
| 22 | A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 250-258. | 1.7 | 44 |
| 23 | Olfactory dysfunction in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 976-981. | 3.7 | 28 |
| 24 | Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Review of Neurotherapeutics, 2018, 18, 871-886. | 2.8 | 18 |
| 25 | A stocked toolbox for understanding the role of astrocytes in disease. Nature Reviews Neurology, 2018, 14, 351-362. | 10.1 | 53 |
| 26 | Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain, 2018, 141, 2561-2575. | 7.6 | 50 |
| 27 | Serial in vivo imaging of transplanted allogeneic neural stem cell survival in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2017, 289, 96-102. | 4.1 | 11 |
| 28 | Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105. | 1.9 | 68 |
| 29 | MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. Journal of Neuroscience, 2017, 37, 5574-5586. | 3.6 | 66 |
| 30 | Sporadic ALS Astrocytes Induce Neuronal Degeneration InÂVivo. Stem Cell Reports, 2017, 8, 843-855. | 4.8 | 105 |
| 31 | What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 98-103. | 1.7 | 15 |
| 32 | Motoneuron Disease: Basic Science. Advances in Neurobiology, 2017, 15, 163-190. | 1.8 | 5 |
| 33 | Motoneuron Disease: Clinical. Advances in Neurobiology, 2017, 15, 191-210. | 1.8 | 2 |
| 34 | Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Molecular Neurodegeneration, 2017, 12, 76. | 10.8 | 49 |
| 35 | Erratum. Advances in Neurobiology, 2017, 15, E1-E1. | 1.8 | 1 |
| 36 | Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (Pâ€Glycoprotein) in endothelial cells of the bloodâ€“brain barrier in mutant superoxide dismutase 1â€linked amyotrophic lateral sclerosis. Glia, 2016, 64, 1298-1313. | 4.9 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Reports, 2016, 15, 2301-2312. | 6.4 | 141 |
| 38 | Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105. | 0.7 | 17 |
| 39 | Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia, 2016, 64, 1154-1169. | 4.9 | 114 |
| 40 | Generation of <scp>GFAP::GFP</scp> astrocyte reporter lines from human adult fibroblastâ€derived i<scp>PS</scp> cells using zincâ€finger nuclease technology. Glia, 2016, 64, 63-75. | 4.9 | 26 |
| 41 | A Spontaneous Missense Mutation in Branched Chain Keto Acid Dehydrogenase Kinase in the Rat Affects Both the Central and Peripheral Nervous Systems. PLoS ONE, 2016, 11, e0160447. | 2.5 | 16 |
| 42 | Hemiparetic Primary Lateral Sclerosis: Revisiting Mills Syndrome. Case Reports in Neurology, 2015, 7, 191-195. | 0.7 | 7 |
| 43 | Preâ€morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 52, 339-343. | 2.2 | 25 |
| 44 | A Comprehensive Library of Familial Human Amyotrophic Lateral Sclerosis Induced Pluripotent Stem Cells. PLoS ONE, 2015, 10, e0118266. | 2.5 | 45 |
| 45 | Human glial progenitor engraftment and gene expression is independent of the ALS environment. Experimental Neurology, 2015, 264, 188-199. | 4.1 | 21 |
| 46 | Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS). Brain Research, 2015, 1628, 343-350. | 2.2 | 39 |
| 47 | Human iPS cell-derived astrocyte transplants preserve respiratory function after spinal cord injury. Experimental Neurology, 2015, 271, 479-492. | 4.1 | 61 |
| 48 | Transplantation of Glial Progenitors That Overexpress Glutamate Transporter GLT1 Preserves Diaphragm Function Following Cervical SCI. Molecular Therapy, 2015, 23, 533-548. | 8.2 | 35 |
| 49 | Induced pluripotent stem cells from ALS patients for disease modeling. Brain Research, 2015, 1607, 15-25. | 2.2 | 57 |
| 50 | C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature, 2014, 507, 195-200. | 27.8 | 779 |
| 51 | Electrical impedance myography correlates with standard measures of Als severity. Muscle and Nerve, 2014, 49, 441-443. | 2.2 | 61 |
| 52 | Gene Profiling of Human Induced Pluripotent Stem Cell-Derived Astrocyte Progenitors Following Spinal Cord Engraftment. Stem Cells Translational Medicine, 2014, 3, 575-585. | 3.3 | 37 |
| 53 | RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron, 2013, 80, 415-428. | 8.1 | 785 |
| 54 | Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Experimental Neurology, 2013, 250, 250-259. | 4.1 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Multimodal Actions of Neural Stem Cells in a Mouse Model of ALS: A Meta-Analysis. Science Translational Medicine, 2012, 4, 165ra164. | 12.4 | 91 |
| 56 | Glia: an emerging target for neurological disease therapy. Stem Cell Research and Therapy, 2012, 3, 37. | 5.5 | 24 |
| 57 | Electrical impedance myography as a biomarker to assess ALS progression. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 439-445. | 2.1 | 125 |
| 58 | Sciatic nerve tumor and tumor-like lesionsâ€"uncommon pathologies. Skeletal Radiology, 2012, 41, 763-774. | 2.0 | 55 |
| 59 | Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS. PLoS ONE, 2011, 6, e25968. | 2.5 | 107 |
| 60 | Spatial and temporal changes in promoter activity of the astrocyte glutamate transporter GLT1 following traumatic spinal cord injury. Journal of Neuroscience Research, 2011, 89, 1001-1017. | 2.9 | 35 |
| 61 | Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury. Glia, 2011, 59, 1996-2005. | 4.9 | 48 |
| 62 | New Treatments in Amyotrophic Lateral Sclerosis. Neuropsychopharmacology, 2011, 36, 370-372. | 5.4 | 1 |
| 63 | Astrocytes carrying the superoxide dismutase 1 (SOD1 <sup>G93A</sup> ) mutation induce wild-type motor neuron degeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17803-17808. | 7.1 | 194 |
| 64 | Stem Cell Transplantation for Spinal Cord Neurodegeneration. Methods in Molecular Biology, 2011, 793, 479-493. | 0.9 | 6 |
| 65 | Peripheral hyperstimulation alters site of disease onset and course in SOD1 rats. Neurobiology of Disease, 2010, 39, 252-264. | 4.4 | 36 |
| 66 | Stem cells and the ALS neurologist. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 417-423. | 2.1 | 15 |
| 67 | Advances in stem cell research for Amyotrophic Lateral Sclerosis. Current Opinion in Biotechnology, 2009, 20, 545-551. | 6.6 | 45 |
| 68 | Rethinking a drug treatment failure on a traditional ALS target. Experimental Neurology, 2009, 216, 254-257. | 4.1 | 1 |
| 69 | Adult glial precursor proliferation in mutant SOD1<sup>G93A</sup> mice. Glia, 2008, 56, 200-208. | 4.9 | 81 |
| 70 | Focal transplantationâ€"based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nature Neuroscience, 2008, 11, 1294-1301. | 14.8 | 403 |
| 71 | Protective Role of Reactive Astrocytes in Brain Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 468-481. | 4.3 | 441 |
| 72 | Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. Experimental Neurology, 2008, 211, 423-432. | 4.1 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Impaired SDF1/CXCR4 signaling in glial progenitors derived from SOD1G93A mice. Journal of Neuroscience Research, 2007, 85, 2422-2432. | 2.9 | 19 |
| 74 | Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Research, 2007, 1185, 256-265. | 2.2 | 112 |
| 75 | Mechanisms of Disease: astrocytes in neurodegenerative disease. Nature Clinical Practice Neurology, 2006, 2, 679-689. | 2.5 | 700 |
| 76 | Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1G93A mice. Experimental Neurology, 2006, 201, 120-130. | 4.1 | 113 |
| 77 | Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALS. Neurobiology of Disease, 2006, 21, 110-118. | 4.4 | 63 |
| 78 | Recovery from paralysis in adult rats using embryonic stem cells. Annals of Neurology, 2006, 60, 32-44. | 5.3 | 266 |
| 79 | Glial restricted precursors protect against chronic glutamate neurotoxicity of motor neurons in vitro. Glia, 2005, 50, 145-159. | 4.9 | 40 |
| 80 | Viral-Induced Spinal Motor Neuron Death Is Non-Cell-Autonomous and Involves Glutamate Excitotoxicity. Journal of Neuroscience, 2004, 24, 7566-7575. | 3.6 | 96 |
| 81 | Altered expression of the glutamate transporter EAAT2b in neurological disease. Annals of Neurology, 2004, 55, 469-477. | 5.3 | 122 |
| 82 | Glutamate transporter expression and function in human glial progenitors. Glia, 2004, 45, 133-143. | 4.9 | 74 |
| 83 | Glutamate transporters: animal models to neurologic disease. Neurobiology of Disease, 2004, 15, 461-473. | 4.4 | 321 |
| 84 | Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neuroscience Letters, 2003, 338, 107-110. | 2.1 | 48 |
| 85 | Human Embryonic Germ Cell Derivatives Facilitate Motor Recovery of Rats with Diffuse Motor Neuron Injury. Journal of Neuroscience, 2003, 23, 5131-5140. | 3.6 | 239 |
| 86 | Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1604-1609. | 7.1 | 766 |
| 87 | Amyotrophic Lateral Sclerosis: Pathogenesis, Differential Diagnoses, And Potential Interventions. Journal of Spinal Cord Medicine, 2002, 25, 262-273. | 1.4 | 12 |